Effect of p-chloramphetamine on the inactivation of monoamine oxidase in rat brain by 3-amino-2-oxazolidinone, 2-hydroxyethylhydrazine and pheylisopropylhydrazine.
p-Chloroamphetamine protected against the irreversible inactivation of monoamine oxidase in rat brain and liver by 3-amino-2-oxazolidinone, an agent that leads to monoamine oxidase inhibition through conversion to an active metabolite, probably 2-hydroxyethyl-hydrazine. In contrast, p-chloramphetamine did not protect against the inactivation of monoamine oxidase by 2-hydroxyethylhydrazine itself or by phenylisoprophylhydrazine. The effect on 3-amino-2-oxazolidinone may have been due to interference with its metabolism rather than to occupancy of active sites on monoamine oxidase by p-chloroamphetamine. Some implications of these findings relating ot the use of 3-amino-2-oxazolidinone in evaluating reversible monoamine oxidase inhibitors and to the pharmacological effects of p-chloroamphetamine are discussed.
D000662:Amphetamines / Q000494:pharmacology*; D000818:Animals; D001921:Brain / Q000201:enzymology*; D004347:Drug Interactions; D006834:Hydrazines / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D066298:In Vitro Techniques; D008099:Liver / Q000201:enzymology; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000037:antagonists & inhibitors*; D010080:Oxazoles / Q000494:pharmacology*; D010659:Phenylhydrazines / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D051381:Rats; D010133:p-Chloroamphetamine / Q000494:pharmacology*
D000662:Amphetamines; D006834:Hydrazines; D008996:Monoamine Oxidase Inhibitors; D010080:Oxazoles; D010659:Phenylhydrazines; D010133:p-Chloroamphetamine